A new study found that chronic wasting disease can sometimes spread silently, with infectious prions present even in animals that show no symptoms. While there is no confirmed human risk, researchers say the disease’s ability to evolve and spread across species warrants close attention.

Many people prescribed GLP-1 drugs for type 2 diabetes (such as Victoza, Ozempic, or tirzepatide) stop taking them, but a surprising number later return to treatment. Researchers found that newer medications appear to keep patients on therapy longer, while side effects remain a major reason for discontinuation.

A large real-world study suggests semaglutide (Ozempic, Wegovy, Rybelsus) may offer an unexpected bonus for people with type 2 diabetes: stronger protection against bone fractures while delivering greater weight loss. Researchers analyzing health records from nearly 60,000 adults found that people taking semaglutide experienced about 15% fewer fractures than those using other common weight-loss medications, despite losing more weight.

Humans evolved to pay close attention to danger, but today that instinct is being overwhelmed by an endless supply of bad news from around the world. Researchers say the answer isn’t to stop following current events—it’s to build healthier habits around how, when, and where we get our news.

A copper-based compound restored the brain’s ability to clear toxic Alzheimer’s proteins, dramatically reducing amyloid buildup and improving memory in laboratory experiments. The findings point to a potentially fast-tracked new treatment strategy because the drug has already been tested in humans for other neurological conditions.